Litigation

Novartis Pharmaceuticals Corp. v. Apotex Inc.

Settled

1:18-cv-01038

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: U.S. District Court for the District of Delaware
Filed: 2018-07-13

Patents at issue (1)

Plaintiffs (1)

π Novartis Pharmaceuticals Corp.

Defendants (1)

Δ Apotex Inc.

Summary

ANDA/Hatch-Waxman suit against Apotex asserting the '405 patent; resolved by confidential settlement licensing entry before patent expiry.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 9187405-1-18-cv-01038 · edit in Admin

Further reading

Cost of Inter Partes Review (IPR): a 2026 breakdown
An IPR ends most cases when the prior art is real. The all-in cost is roughly a tenth of full litigation — but only if you stage it right.
Joint defense groups: economics, formation, and the privilege framework
An NPE sues twenty defendants on one patent. Solo, each faces $3-5M in defense costs. Pooled into a joint defense group, the per-defendant number drops to $200-500K. The economics only work if the privilege framework is set up correctly.
Most-litigated US patents: 12 patents that defined the patent troll era
If a demand letter lands on your desk citing one of these, you are not the first. The campaign playbook is on file. The defenses other defendants used are public record.
Non-Practicing Entity (NPE) lawsuit defense: a defendant's playbook
Defending an NPE suit is different from defending a competitor's suit. The asymmetries cut both ways — and the right plays exploit the ones that favor the defendant.
The patent litigation lifecycle
Most patent cases never reach trial. A defendant who understands the lifecycle makes better decisions about when to fight, when to settle, and when to invest in IPR — instead of overspending on whatever phase they happen to be in.

All resources →